Abstract

Drug Resistant TB is a challenge for a country like India where there is highest prevalence of MDR cases in the world. With decentralizing and smooth accessibility of the Gene Xpert, it has become quick and easy to rule out the drug resistance. Unlike the conventional CAT-IV treatment of about 24 months, a newer shorter regimen of MDR TB treatment has been started in selected cases like pulmonary MDR-TB (when there is no resistance of FQs% or SLIs on the second line LPA). We herein, present a case of secondary pulmonary MDR-TB, who has been started on a newer shorter MDR regimen treatment for the first time at a very large and heavily burdened center in the Western part of the national capital of India. Keywords: Gene Xpert; LPA; MDR; SLI; TB.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call